These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 2123914)

  • 1. Long-term haemodynamic effects of isosorbide 5-mononitrate in patients with cirrhosis and portal hypertension.
    García-Pagán JC; Feu F; Navasa M; Bru C; Ruiz del Arbol L; Bosch J; Rodés J
    J Hepatol; 1990 Sep; 11(2):189-95. PubMed ID: 2123914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of isosorbide-5-mononitrate on variceal pressure and systemic and splanchnic haemodynamics in patients with cirrhosis.
    Escorsell A; Feu F; Bordas JM; García-Pagán JC; Luca A; Bosch J; Rodés J
    J Hepatol; 1996 Apr; 24(4):423-9. PubMed ID: 8738728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The acute and chronic effects of isosorbide-5-mononitrate on portal haemodynamics in cirrhosis.
    Grose RD; Plevris JN; Redhead DN; Bouchier IA; Hayes PC
    J Hepatol; 1994 Apr; 20(4):542-7. PubMed ID: 8051395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different haemodynamic effects of a single dose of long-acting isosorbide-5-mononitrate in healthy subjects and patients with cirrhotic portal hypertension.
    Piscaglia F; Donati G; Gaiani S; Gramantieri L; Leoni S; Mancini M; Bolondi L
    Dig Liver Dis; 2004 Sep; 36(9):594-602. PubMed ID: 15460844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of portal pressure by isosorbide-5-mononitrate in patients with cirrhosis. Effects on splanchnic and systemic hemodynamics and liver function.
    Navasa M; Chesta J; Bosch J; Rodés J
    Gastroenterology; 1989 Apr; 96(4):1110-8. PubMed ID: 2925055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of portal pressure reduction by the association of isosorbide-5-mononitrate to propranolol administration in patients with cirrhosis.
    Garcia-Pagán JC; Navasa M; Bosch J; Bru C; Pizcueta P; Rodés J
    Hepatology; 1990 Feb; 11(2):230-8. PubMed ID: 2307401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect and mechanism of action of isosorbide-5-mononitrate.
    Hayes PC; Westaby D; Williams R
    Gut; 1988 Jun; 29(6):752-5. PubMed ID: 3384359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. A randomized controlled study.
    García-Pagán JC; Feu F; Bosch J; Rodés J
    Ann Intern Med; 1991 May; 114(10):869-73. PubMed ID: 2014947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute administration of carvedilol is more effective than propranolol plus isosorbide-5-mononitrate in the reduction of portal pressure in patients with viral cirrhosis.
    Lin HC; Yang YY; Hou MC; Huang YT; Lee FY; Lee SD
    Am J Gastroenterol; 2004 Oct; 99(10):1953-8. PubMed ID: 15447755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic and regional hemodynamic effects of isosorbide dinitrate in patients with liver cirrhosis and portal hypertension.
    Mols P; Hallemans R; Melot C; Lejeune P; Naeije R
    J Hepatol; 1989 May; 8(3):316-24. PubMed ID: 2732445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of effects of isosorbide-5-mononitrate on hepatic hemodynamics in HBsAg-positive cirrhosis.
    Tsai YT; Lee FY; Lin HC; Chang TT; Lay CS; Wang SS; Kong CW; Lee SD; Lo KJ
    Hepatology; 1989 Sep; 10(3):283-7. PubMed ID: 2759546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis: long-term hemodynamic and renal effects.
    Morillas RM; Planas R; Cabré E; Galán A; Quer JC; Feu F; García Pagán JC; Bosch J; Gassull MA
    Hepatology; 1994 Dec; 20(6):1502-8. PubMed ID: 7982651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Propranolol and 5-isosorbide mononitrate in patients with cirrhosis: systemic and portal hemodynamic events].
    Castaño G; Viudez P; Sookoian S; Carlevaro O; Riccitelli M; Frider B
    Gastroenterol Hepatol; 2000; 23(6):275-81. PubMed ID: 15324622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Portal and systemic haemodynamic response to acute and chronic administration of low and high dose isosorbide-5-mononitrate in patients with cirrhosis.
    Jones AL; Bangash IH; Walker J; Simpson KJ; Finlayson ND; Hayes PC
    Gut; 1995 Jan; 36(1):104-9. PubMed ID: 7890211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of peroral administration of isosorbide dinitrate on portal pressure and blood flow in patients with cirrhosis of the liver.
    Cervinka J; Kordac V; Kalab M
    J Int Med Res; 1989; 17(6):560-4. PubMed ID: 2628133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical vs haemodynamic response to drugs in portal hypertension.
    McCormick PA; Patch D; Greenslade L; Chin J; McIntyre N; Burroughs AK
    J Hepatol; 1998 Jun; 28(6):1015-9. PubMed ID: 9672178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of portal pressure by chronic administration of isosorbide dinitrate in patients with cirrhosis: effects on systemic and splanchnic hemodynamics and liver function.
    Ikegami M; Toyonaga A; Tanikawa K
    Am J Gastroenterol; 1992 Sep; 87(9):1160-4. PubMed ID: 1519573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemodynamic evaluation of the addition of isosorbide-5-mononitrate to nadolol in cirrhotic patients with insufficient response to the beta-blocker alone.
    Merkel C; Sacerdoti D; Bolognesi M; Enzo E; Marin R; Bombonato G; Angeli P; Gatta A
    Hepatology; 1997 Jul; 26(1):34-9. PubMed ID: 9214449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of isosorbide dinitrate on portal hypertension in alcoholic cirrhosis.
    Merkel C; Finucci G; Zuin R; Bazzerla G; Bolognesi M; Sacerdoti D; Gatta A
    J Hepatol; 1987 Apr; 4(2):174-80. PubMed ID: 3584925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duplex Doppler ultrasonography allows a multiorgan noninvasive approach to splanchnic pharmacodynamics in patients with cirrhosis.
    Bolognesi M; Sacerdoti D; Merkel C; Caregaro L; Bellon S; Gatta A
    Bildgebung; 1995 Jun; 62(2):138-43. PubMed ID: 7663138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.